Benefícios da Medicina Hiperbárica e Epigenética na Síndrome de Crohn. Caso clínico.
Revista ft · 08.06.2026 · 30 (159) · 01-09
DOI: 10.69849/35t82621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 08.06.2026. Verfasst von Marcel Simonetti und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Crohn's disease is a chronic transmural and autoimmune inflammatory disease of the digestive tract of unknown etiology, influenced by genetic and environmental factors. Epigenetics — that is, changes in gene expression without modifying DNA — plays a fundamental role, as chronic inflammation alters DNA methylation, causing persistent pro-inflammatory changes in stem cells and tissues. There are key points regarding epigenetics and Crohn's disease. Continuous inflammation in the digestive tract alters epigenetic marks, contributing to the chronicity and severity of the disease. The anti-inflammatory effects, together with the stimulation of healing and tissue repair produced by hyperbaric oxygen therapy (HBOT), are highly beneficial for patients with this disease and/or ulcerative colitis. Evidence of these clinical outcomes has led to the increasing introduction of hyperbaric medicine into treatment protocols for inflammatory bowel diseases.
Zitieren
APA
Simonetti, M., & Benítez, M. (2026). Benefícios da Medicina Hiperbárica e Epigenética na Síndrome de Crohn. Caso clínico. Revista ft, 30(159), 01-09. https://doi.org/10.69849/35t82621
Vancouver
Simonetti M, Benítez M. Benefícios da Medicina Hiperbárica e Epigenética na Síndrome de Crohn. Caso clínico. Revista ft. 2026;30(159):01-09. doi:10.69849/35t82621
BibTeX
@article{Simonetti2026,
author = {Simonetti, Marcel and Benítez, Mariana},
title = {Benefícios da Medicina Hiperbárica e Epigenética na Síndrome de Crohn. Caso clínico},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {159},
pages = {01--09},
doi = {10.69849/35t82621}
}
EUVIMED